Stand Up To Cancer and SandboxAQ Launch Collaboration to Advance Treatment Innovation

The initiative will use SandboxAQ's LQM technology to accelerate new approaches that help treat cancer earlier, when it is most treatable

LOS ANGELES, June 5, 2025 /PRNewswire/ -- Stand Up To Cancer^® (SU2C) and SandboxAQ today announced a collaboration that brings SandboxAQ's Large Quantitative Models (LQMs) to SU2C-funded cancer research projects. The initiative aims to accelerate the development of new treatments.

SU2C and SandboxAQ will collaborate to support high-impact cancer research, including efforts to detect hard-to-diagnose and treat cancers, as well as leveraging predictive modeling to optimize treatment response and monitor potential recurrence.

The new program aims to leverage advanced AI and powerful data modeling tools from SandboxAQ to help find early warning signs of disease, predict how illnesses might develop, and create more personalized ways to treat patients.

"This is a pivotal moment in cancer research. We stand at the threshold of a new era, with emerging tools that have the potential to catch cancer earlier and treat it more precisely than ever before," said Julian Adams, Ph.D., president and CEO of Stand Up To Cancer. "SandboxAQ brings cutting-edge technology that complements our scientific network and collaborative model. Together, we can turn breakthroughs in the lab into more lives saved."

This new collaboration unites SU2C's proven ability to drive bold, multi-institutional research with SandboxAQ's expertise in AI-driven discovery. Together, the organizations aim to push the boundaries of what's possible in precision treatment by integrating powerful computational tools directly into the cancer research process.

"We're excited to bring SandboxAQ's technologies to the fight against cancer," said Jack Hidary, CEO of SandboxAQ. "In collaboration with Stand Up To Cancer, we will support researchers with our AI LQM platform to model complex biological systems, and accelerate the translation of oncology research into patient impact. This collaboration brings us closer to a future where more cancers are cured."

This initiative reflects SU2C's ongoing commitment to pairing bold, collaborative science with the most advanced tools available. By integrating next-generation technology into SU2C's research programs, the organization continues to evolve its approach to funding and accelerating the most promising cancer breakthroughs.

Since its inception in 2008, SU2C has funded more than 3,100 scientists from more than 210 institutions in 16 countries. This collaboration aligns with SU2C's bold goal to decrease cancer mortality by 25% within the next five years and 50% over the next decade by making early-stage cancer detection a standard of care.

More details about the specific SU2C research teams involved in this collaboration will be announced as fundraising milestones are reached and grants are awarded.

About Stand Up To Cancer
Stand Up To Cancer^® (SU2C) raises awareness and funds research to detect and treat cancers with the aspiration to cure all patients. SU2C is a 501(c)(3) charitable organization and was initially launched as a division of the Entertainment Industry Foundation.  Established in 2008 by media and entertainment leaders, SU2C utilizes these communities' resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of April 2024, more than 3,100 scientists representing more than 210 institutions are involved in SU2C-funded research projects.

As SU2C's scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee, led by William G. Nelson, M.D., Ph.D., conduct rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Current members of the SU2C Founders and Advisors Committee (FAC) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Julian Adams, Ph.D., serves as SU2C's president and CEO.

For more information visit StandUpToCancer.org, Instagram, TikTok, X, Facebook, and YouTube.

About SandboxAQ
SandboxAQ is a B2B company delivering solutions at the intersection of AI and quantum techniques. The company's Large Quantitative Models (LQMs) deliver critical advances in life sciences, financial services, navigation, and other sectors. The company emerged from Alphabet Inc. as an independent, growth-backed company funded by leading investors and strategic partners including funds and accounts advised by T. Rowe Price Associates, Inc., Alger, IQT, US Innovative Technology Fund, S32, Paladin Capital, BNP Paribas, Eric Schmidt, Breyer Capital, Ray Dalio, Marc Benioff, Thomas Tull, Yann LeCun, and others. For more information, visit http://www.sandboxaq.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/stand-up-to-cancer-and-sandboxaq-launch-collaboration-to-advance-treatment-innovation-302473843.html

SOURCE Stand Up To Cancer